BackExact Sciences Overview

Exact Sciences Total Revenue

Latest total revenue for EXAS: $3.2B, below the Healthcare sector average of $110B.

Get informed when a big investor buys or sells

+ Follow

Quarterly Revenue

$878.38M
23.12% YoY

As of Dec 2025

Annual Revenue (TTM)

$3.25B
17.69% YoY

Trailing 12 months ending Dec 2025

Average Revenue (Comparison Companies)

Loading

Total Revenue History

Loading

Total Revenue Comparison

Loading

Annual Revenue Growth Rate (%)

Loading

Annual Revenue Growth (Absolute)

Loading

Exact Sciences (EXAS) FAQ

Exact Sciences posts a total revenue of $3.2B as of December 2025. That compares with $2.8B in the prior-year period — up 17.7% year over year. That is below the Healthcare sector average of $110B. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Exact Sciences's total revenue was $2.8B. The latest reading is $3.2B — a 17.7% year-over-year increase (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a total revenue near $110B is typical. Exact Sciences's $3.2B is lower that level. That is roughly 97.0% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Total Revenue is one piece of Exact Sciences's financial statement story. At $3.2B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for EXAS's total revenue usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $110B), and (3) consistency with growth and profitability. This page covers the first two; Exact Sciences's other metric pages and overview cover the third.